Published: 2022-06-28

Drug misuse by teenagers in schools in Benin and genetic polymorphism of cytochrome p450: interest and perspectives of cytochrome p450 genotyping

Arnaud Coffi Agbanlinsou, Ibrahim Cisse, Anatole Laleye


The misuse of psychoactive substances by students is a reality in Beninese schools. These students are exposed to experimentation with these substances with or without prescriptions. The systematic genotyping of cytochromes in these students and in general in subjects exposed to the use of psychoactive substances would be an asset in their therapeutic management and more specifically in the adaptation of dosages and will also allow us to add a particular touch during sensitizations on the experimentation of substances. To achieve this, we checked the availability of drugs that metabolize by cytochromes 2D6 and 3A4 and that are in pharmacies in Benin. What would happen when they consume one or more substances that are metabolized by two cytochrome? PharmGKB is a pharmacogenomics knowledge base that provides information on how human genetic variation affects drug response by collecting information on clinically relevant gene-drug associations and genotype-phenotype relationships. For dosage individualization in therapeutics, the use of the PharmGKB knowledge base preceded by cytochrome genotyping in exposed subjects are assets that clinicians should make use of today for disease treatment.


Misuse, Psychoactive substances, Cytochromes, Students, PharmGKB

Full Text:



Certification of health care organisations, educational sheet-Medicines: Evaluation of drug management drug management according to the certification standard. Available at: publications/. Accessed on 20 October 2021.

Kpatchavi AC, Adounkpe F. Drug Use and Addictive Substances Among Adolescents in Benin: A Survey of High Schools in Cotonou. Ann Univ Lomé, SérieLett. 2016;4:239-49.

Tripathi N, Mousa OY. Hepatitis B. Treasure Island, FL: StatPearls Publishing; 2022.

Jules D. Importance of cytochromes P450: pharmacogenetics and drug interactions. Pharma-Flash. 2010;37:7-10.

Charlotte AJ. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf. 1993;9(1):51-9.

Pirmohamed M, James SM. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. Lat Am J Pharm. 2004;329:15-8.

Sultana J, Cutroneo PGT. Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother. 2013;4(1):73-8.

Ingelman-Sundberg MO. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. TIPS. 1999;20(1):342-8.

Lhermitte M, Allorge D, Broly F, Launois B. Xenobiotic-metabolizing polymorphic enzymes. An opportunity for individualized drug treatment. Bull Acad Natl Med. 2006;3:42.

Sundberg M. Pharmacogenetics: An opportunity for a safer and more efficient pharmacotherapy. J Intern Med. 2001;250(3):186-200.

Samer CF, Valérie Piguet PD. Analgesia, the importance of cytochrome P450 2D6 genetic polymorphism in therapeutic individualisation. Douleurs Analg. 2004;2:63-6.

Samer CF, Valérie Piguet PD. Genetic polymorphism and drug interactions: Their importance in pain management. Can J Anesth. 2005;52(8):806-21.

Zhou Y, Ingelman-Sundberg M, Lauschke V. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther. 2017;102(4):688-700.

Aigrain E, Panserat S, Sica RK. Molecular genetics of cytochrome P450 llD: abnormalities in drug metabolism. Rev Française d’allergologie d’Immunol Clin. 1995;35(5):462-9.

Rogers JF, Nafziger AN. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med. 2002;113(9):746-50.

Marsousi N, Ancrenaz V, Rudaz S, Samer C, Desmeules J. Influence of genetic polymorphisms on the response variability to opioids. Douleur Analg. 2013;26(4):203-8.

Bertz RJ, Granneman GR. Use of in Vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmocokinet. 1997;32(3):210-58.

Zone industrielle d’Akpakpa, Cotonou. Available at: Accessed on 20 October 2021.

Sim SC, Ingelman-Sundberg M. The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum Genomics. 2010;4(4):278-81.

Kozyra M, Ingelman-Sundberg M, Lauschke VM. Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. Genet Med. 2017;19(1):20-9.

Rajman I, Knapp L, Morgan T, Masimirembwa C. African genetic diversity: implications for cytochrome P450-mediated drug metabolism and drug development. EBio Med. 2017;17:67-74.

Kabre E, Karfo RBK. Genetic polymorphism of cytochromes p450: a systematic review of primary studies in the African population. J la Société Biol Clin du Bénin. 2017;27:38-46.

Daniel LH. Polymorphisms of cytochrome P450 are potential candidates that could potentially help clinicians on the treatment of cardiovascular diseases among Asian populations. Indian Heart J. 2017;69(5):655-6.

Anne LB. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenom. 2002;3(2):229-43.

Wang Y, Zhao X, Lin J, Li H, Johnston SC, Lin Y, et al. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. J Am Med Assoc. 2016;316(1):70-8.

Bagheri A, Haghshenas BKM. Prevalence of the CYP2D6, Iranians of different ethnicities. Drug Des Devel Ther. 2015;9:2627-34.

Volker M. Lauschke MIS. Prediction of drug response and adverse drug reactions : From twin studies to Next Generation Sequencing. Eur J Pharm Sci. 2019;130(1):65-77.

PharmGKB. Available at: Accessed on 20 October 2021.